Stock Markets July 23, 2026 03:45 PM

Teladoc, GoodRx Stocks Slip After OpenAI Adds Health Data Integration to ChatGPT

OpenAI enables US users to link medical records and Apple Health to ChatGPT; company highlights new GPT-5.6 Sol model for paid users

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
TDOC GDRX

Shares of Teladoc and GoodRx moved lower after OpenAI rolled out a ChatGPT feature allowing U.S. users to connect Apple Health and supported medical records. The update, paired with a new paid model billed as superior for health tasks, comes with built-in privacy protections and physician-designed evaluations.

Teladoc, GoodRx Stocks Slip After OpenAI Adds Health Data Integration to ChatGPT
TDOC GDRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Teladoc shares dropped 2.8% and GoodRx shares declined 2.6% after OpenAI announced ChatGPT can connect to Apple Health and supported US medical records.
  • The feature is available to logged-in ChatGPT users aged 18 and older in the US on web and iOS across Free, Go, Plus, and Pro plans and aims to let users compare labs, summarize appointment changes, and analyze activity-sleep patterns.
  • OpenAI launched GPT-5.6 Sol for paid users and provides GPT-5.5 Instant for free users; the company worked with physicians to create evaluations measuring accuracy, safety, communication, and completeness.

Shares of Teladoc Inc (NYSE:TDOC) fell 2.8% and GoodRx Holdings Inc (NASDAQ:GDRX) slipped 2.6% on Thursday following OpenAI's announcement of a new ChatGPT health feature that permits users to link personal medical records and Apple Health data to the chatbot.

The feature, which is available to logged-in ChatGPT users aged 18 and older in the United States on web and iOS, supports connections to Apple Health and medical records from certain US hospital systems as well as One Medical and Function Health. OpenAI said more than 300 million people use ChatGPT weekly for health-related questions.

OpenAI outlined several capabilities that the connected-data feature will enable. Users can ask the chatbot to compare current lab results with prior tests, summarize what has changed since medical appointments, or assess how sleep and activity patterns relate to daily routines. The functionality is accessible across Free, Go, Plus, and Pro subscription tiers.

For paid customers, OpenAI deployed GPT-5.6 Sol, which the company described as its strongest model for health tasks. Free users retain access to GPT-5.5 Instant. OpenAI said it collaborated with physicians to develop evaluations that measure accuracy, safety, communication, and completeness of the system's health-related outputs.

The company said an early finding from testing was that more than 70% of health-related conversations happened outside a dedicated health space in ChatGPT, prompting OpenAI to integrate the connected-data feature across all conversations rather than confining it to a separate health environment.

OpenAI emphasized that users must grant permission before ChatGPT can access any connected health information. The company stated that connected medical records and Apple Health data are not used to train its foundation models or to target advertisements. It also said all ChatGPT conversations are encrypted at rest and in transit, with additional encryption protections applied specifically to health information.

Users retain control over their connections to health data. OpenAI said individuals can disconnect their health information at any time, and that data will be deleted from its systems within 30 days after disconnection.


Context for markets

The market reaction - modest declines in the shares of two companies focused on telehealth and consumer health services - came on the same day the new ChatGPT capability and model deployment were announced. The announcement couples expanded functionality for consumers with assurances about consent and data handling.

Risks

  • Accuracy and safety of AI-driven health guidance - OpenAI said it developed physician-led evaluations to measure accuracy and safety, indicating those remain key considerations for clinical reliability.
  • Data privacy and control - while OpenAI states connected records are not used to train foundation models and that conversations are encrypted, users must grant permission and may be concerned about data handling until they disconnect and data is deleted within 30 days.
  • Market uncertainty for telehealth and consumer health services - modest share declines for Teladoc and GoodRx reflect investor sensitivity to large tech firms integrating health-related features, with potential implications for competitive dynamics in the sector.

More from Stock Markets

Nikkei Drops Over 2% as AI Spending Concerns Trigger Tech Sell-Off Jul 23, 2026 Scribe Therapeutics Prices IPO at $15, Raising About $128.7 Million Before Fees Jul 23, 2026 SpaceX pushes Starship's 13th test flight to Friday due to poor visibility at Starbase Jul 23, 2026 China’s AI Buildout: From Chips to Cloud, Markets Price a Multi-Year Push Jul 23, 2026 ASX CFO Andrew Tobin to retire as exchange completes CEO search Jul 23, 2026